MNTL — Tema Neuroscience and Mental Health ETF
Data updated: 2025-07-24
MNTL — Tema Neuroscience and Mental Health ETF. United States Multi-Cap / All-Cap Growth Health Care Equity. Holdings, fees, performance and SEC filings.
MNTL Fund Overview
MNTL — Tema Neuroscience and Mental Health ETF is a US ETF managed by Tema ETF Trust, categorised as United States Multi-Cap / All-Cap Growth Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: Tema ETF Trust
- Category: United States Multi-Cap / All-Cap Growth Health Care Equity
- Assets under management: $9.71M
- 1-year return: -9.0%
- Ticker: MNTL
- SEC CIK: 0001944285
- SEC series ID: S000081543
- Share class ID: C000244457
MNTL Investment Objective and Strategy
Tema Neuroscience and Mental Health ETF describes its objective and strategy as follows, from its latest prospectus filed with the SEC by Tema ETF Trust.
Investment objective
Tema Neuroscience and Mental Health ETF (the Fund) seeks to provide long-term growth of capital.
Principal investment strategy
Under normal circumstances, the Fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in neuroscience and mental health companies. A company is generally considered to be a neuroscience or mental health company that derives at least 50% of revenues from neuroscience or neurology-related diseases, or mental health. The Adviser will use internal research and analysis based on company disclosure (such as 10-K filings, company presentations, capital markets day presentations) and other publicly available sources (e.g., sell-side research, biotechnology industry publications etc.) to make this assessment. Example companies include large pharmaceutical firms, development-stage biotechnology firms, diagnostic focused businesses with products used to diagnose and/or treat neuroscience or mental health illnesses, medical device companies focused on treatment of the aforementioned diseases treatment, and healthcare service providers with a specific strategic focus on helping treat and manage the aforementioned diseases, each providing they meet the aforementioned revenue test.
The Fund generally is expected to consist of more than 15 companies but not more than 100 companies. The number of constituents may change depending on the number of companies available for investment that meet the Funds criteria. To be eligible for inclusion in the Fund, a company must have a market capitalization of at least $100 million and there is no upper limit on the market capitalization of a portfolio company. To be eligible for inclusion in the Fund, a company must have a three-month average daily traded value of at least $500,000. A significant portion of the Funds assets are expected to be invested in the United States and Europe. The Fund will not engage in currency hedging and is expected to own foreign currency for short periods of time for the purposes of buying and selling non-US listed securities and collecting dividends and/or coupon payments from those securities.
The Fund is classified as a non-diversified investment company under the Investment Company Act of 1940, as amended (the 1940 Act), which means that it may invest a high percentage of its assets in a limited number of issuers. The Fund relies on the professional judgment of its Adviser to make decisions about the Funds portfolio investments. The basic investment philosophy of the Adviser is to seek to invest in growth companies within the aforementioned thematic universe that are attractively valued when compared to their fundamentals and potential for earnings growth. The Advisers security selection process for identifying companies within the aforementioned theme uses both top down idea generation (sector, theme, company research) and bottom up security selection (valuation, fundamental, quantitative, qualitative measures) approaches.
In practice top down idea generation means fundamental sector research, quantitative tools (for example screening based on metrics such as five-year historic revenue growth, margins, or returns on invested capital) and the Advisers own expertise, are used to narrow down the specific thematic research universe. Once this is defined bottom up security analysis involves the Adviser comparing valuation multiples (such as free cash flow yield, price to book ratio and price to earnings ratio or enterprise value to total invested capital, among others) to fundamental metrics (such as organic revenue growth, margins, returns on invested capital and equity, among others). Investments are deemed attractively valued when compared to fundamentals if the valuation multiples are below and fundamentals are above either (1) peers (2) the companies own historic averages (3) or prospective forecasts (as determined by the Adviser).
Buttressing this is a detailed fundamental research profile of each company assessing business model, competitive edge, management incentives and track record, and balance sheet. The Adviser integrates environmental, social and corporate governance (ESG) considerations into its investment analysis. This is in support of both the objective of maximizing return and the broader analysis of risks associated with individual companies. The Adviser, however, does not use ESG considerations to limit, restrict or otherwise exclude companies or sectors from the Funds investment universe. ESG factors in this context include, but are not limited to, the impact on or from climate change, natural resource use, waste management practices, human capital management, product safety, supply chain management, corporate governance, business ethics and advocacy for governmental policy.
The Adviser may measure companies when considering ESG factors using sustainability data including scoring information that is provided by (i) the companies themselves, (ii) several third-party data providers (which are subject to change from time to time), including, but not limited to, Refinitiv, FactSet, Trucost, Sustainalytics, SAM ESG Research and Persefoni and (iii) the Adviser itself. While the Fund intends to seek select opportunities to actively engage with one or more portfolio companies, it may only be able to do so in limited circumstances and generally seek to indirectly influence the policies of portfolio companies through voting proxies of such companies. The Fund seeks to encourage transformational change at the public companies within its portfolio through the application of these proxy voting guideline.
In making these considerations the Adviser will use both internal and external data sources and analyses including, but not limited to, those provided by companies directly or by third parties. These considerations also inform monitoring of existing positions. To conduct this Analysis, the Adviser will use its own internal research and analysis, based on company materials (such as annual reports, websites, strategic and sell-side conference presentations) and other sources (publications focused on relevant industries, and external research by sell-side banks or consultancy firms. The Fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The Fund may invest in small-, mid- and large capitalization companies.
The Fund may engage in securities lending.
MNTL Holdings
Top 10 holdings of Tema Neuroscience and Mental Health ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Vertex Pharmaceuticals Inc | 10.46% |
| Regeneron Pharmaceuticals Inc | 6.48% |
| Alnylam Pharmaceuticals Inc | 6.22% |
| Argenx SE | 5.25% |
| Teva Pharmaceutical Industries | 4.99% |
| Neurocrine Biosciences Inc | 4.95% |
| Eli Lilly & Co | 4.16% |
| Crinetics Pharmaceuticals Inc | 4.11% |
| Biogen Inc | 3.34% |
| Stryker Corp | 3.14% |
MNTL Portfolio Allocation
Asset-class allocation of Tema Neuroscience and Mental Health ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 97.6% |
| Cash & Equivalents | 2.3% |
MNTL Performance
Total returns for MNTL (as of 2026-10-01), from SEC filings.
| Period | Total return |
|---|---|
| 1 year | -9.0% |
MNTL Risk Information
Risk metrics for MNTL, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 13.9%
MNTL Costs and Fees
MNTL costs about $75 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.75%
- Gross expense ratio: 0.99%
- Portfolio turnover: 29%
- Brokerage commissions: 1.88 bps of average net assets (SEC N-CEN)
MNTL Cashflows
Over the 12 months to 2025-05, Tema Neuroscience and Mental Health ETF had net inflows of $0, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2025-05 | $0 |
| 2025-04 | $0 |
| 2025-03 | $0 |
| 2025-02 | $0 |
| 2025-01 | $0 |
| 2024-12 | $0 |
MNTL Debt Constituents
No individual debt constituents are reported in Tema Neuroscience and Mental Health ETF's latest SEC N-PORT filing.
MNTL Prospectus and SEC Filings
Official Tema Neuroscience and Mental Health ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2025-06-26
- Prospectus (485BPOS) — filed 2024-06-28
- Prospectus supplement (497) — filed 2024-12-23
- Portfolio holdings (N-PORT) — filed 2025-07-24
- Portfolio holdings (N-PORT) — filed 2025-04-22
- Portfolio holdings (N-PORT) — filed 2025-01-17
- Annual census (N-CEN) — filed 2025-05-13
- Annual census (N-CEN) — filed 2024-04-24
Related Funds
Other United States Multi-Cap / All-Cap Growth Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.